Perspective Therapeutics, Inc. CATX

SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the 38th EORTC-NCI-AACR (ENA) Symposium 2026 on Molecular Targets and Cancer Therapeutics taking place Novemb

Perspective Therapeutics' (CATX) NET program to potentially treat neuroendocrine tumors may be advan

Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotope access and manufacturing capacityVMT-α-NET study update accepted for oral presentation at ESMO 2026VMT01 melanoma and PSV359 FAP-α clinical programs continue to advanceApproximately $237 million in cash, cash equivalents, and short-term investments as of June 3